Akèy › Pirura Trombositopenik Idyopatik
Etid klinik pou Pirura Trombositopenik Idyopatik ap rekrite nan Etazini
17 etid pou Pirura Trombositopenik Idyopatik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Los Angeles, CA7 etid
- Boston, MA6 etid
- Washington, DC6 etid
- Greenville, NC6 etid
- The Bronx, NY5 etid
- Portland, OR4 etid
- Seattle, WA4 etid
- Houston, TX4 etid
- Durham, NC4 etid
- Rochester, MN4 etid
- Philadelphia, PA3 etid
- Cleveland, OH3 etid
- Cedar Rapids, IA3 etid
- Kansas City, MO3 etid
- New Haven, CT3 etid
- New Orleans, LA3 etid
Pa eta
- Arkansas3 etid
- Connecticut3 etid
- Distrik Columbia6 etid
- Florid3 etid
- Illinois4 etid
- Iowa3 etid
- Kalifòni10 etid
- Lwizyàn4 etid
- Massachusetts6 etid
- Michigan3 etid
- Minnesota5 etid
- Missouri3 etid
- New Jersey4 etid
- New York7 etid
- North Carolina7 etid
- Ohio3 etid
- Oregon4 etid
- Pennsylvania3 etid
- Texas4 etid
- Virginia4 etid
- Washington4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07421167A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07786077A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06721013Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07549698A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06722235A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 17, 2026 · NCT07700238Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 14, 2026 · NCT07095127Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07104565A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 11, 2026 · NCT07059000A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06948318OM336 in Autoimmune Cytopenias
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Sep 3, 2026 · NCT07083960Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Ap rekriteFaz 1
Laj 18 a 85 · Tout sèks · Mizajou Jul 22, 2026 · NCT06371417Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT07007962Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou May 12, 2026 · NCT05070845A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 1, 2026 · NCT06544499Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Apr 15, 2026 · NCT04323748Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 10, 2025 · NCT06817395Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.